Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Niklas Klümper (15048887) (author)
مؤلفون آخرون:	Damian J. Ralser (15048890) (author), Jörg Ellinger (15048893) (author), Florian Roghmann (15048896) (author), Julia Albrecht (15048899) (author), Eduard Below (15048902) (author), Abdullah Alajati (15048905) (author), Danijel Sikic (15048908) (author), Johannes Breyer (15048911) (author), Christian Bolenz (15048914) (author), Friedemann Zengerling (15048917) (author), Philipp Erben (15048920) (author), Kristina Schwamborn (15048923) (author), Ralph M. Wirtz (15048926) (author), Thomas Horn (15048929) (author), Dora Nagy (15048932) (author), Marieta Toma (15048935) (author), Glen Kristiansen (15048938) (author), Thomas Büttner (15048941) (author), Oliver Hahn (15048944) (author), Viktor Grünwald (15048947) (author), Christopher Darr (15048950) (author), Eva Erne (15048953) (author), Steffen Rausch (15048956) (author), Jens Bedke (15048959) (author), Katrin Schlack (15048962) (author), Mahmoud Abbas (15048965) (author), Stefanie Zschäbitz (15048968) (author), Constantin Schwab (15048971) (author), Alexander Mustea (15048974) (author), Patrick Adam (15048977) (author), Andreas Manseck (15048980) (author), Bernd Wullich (15048983) (author), Manuel Ritter (15048986) (author), Arndt Hartmann (15048549) (author), Jürgen Gschwend (15048989) (author), Wilko Weichert (15048992) (author), Franziska Erlmeier (15048995) (author), Michael Hölzel (15048998) (author), Markus Eckstein (14949481) (author)
منشور في:	2025
الموضوعات:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Drug Resistance Clinical drug resistance Drug Targets Cell surface receptor drug targets Genitourinary Cancers Bladder cancer Precision Medicine Progression, Invasion & Metastasis Tumor progression Translational Research Tumor Heterogeneity
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
حسب: Niklas Klümper (15048887)
منشور في: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
حسب: Erwin Tomasich (15052256)
منشور في: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
حسب: Jeffrey D. Mandell (14963909)
منشور في: (2025)

Supplementary Figure S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Table S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Table S2 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Table S3 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Table S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
حسب: Abdullah A. Osman (15056323)
منشور في: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
حسب: Min Wei (16918572)
منشور في: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
حسب: Min Wei (16918572)
منشور في: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
حسب: Xiaohong Hong (22681698)
منشور في: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
حسب: Seung Yeon Oh (15051017)
منشور في: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
حسب: Zev A. Wainberg (15047031)
منشور في: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Movie S1 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
حسب: Jill Gallaher (16799594)
منشور في: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
حسب: Jill Gallaher (16799594)
منشور في: (2025)

Movie S3 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
حسب: Jill Gallaher (16799594)
منشور في: (2025)

Movie S4 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
حسب: Jill Gallaher (16799594)
منشور في: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
حسب: Dahihm Kim (16546203)
منشور في: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
حسب: Dahihm Kim (16546203)
منشور في: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
حسب: Dahihm Kim (16546203)
منشور في: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
حسب: Dahihm Kim (16546203)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_l48vmqrgv4bj6iiqvrel28pm7i